新股消息 | 海普瑞公開發售超購逾68倍,以下限18.4港元定價
uSMART友信智投7月1日消息,海普瑞已於昨日中午截止招股。市場消息透露,公開發售錄得68倍超額認購,凍結資金317億港元,有10萬人認購。
根據回撥機制,由於認購倍數處於50-100倍之間,所以公開發售股數占比將由10%增加到40%。重新分配後公開發售手數約17.6萬,即甲乙組分別獲配8.8萬手。
根據彭博報導,海普瑞以招股價區間的下限18.4港元定價,集資金額40.5億港元。海普瑞A股週二收市價為24.86元,即港股定價較之折讓約33%。
海普瑞將於7月7日公佈中簽結果,7月8日上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.